'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"'No discussions' over AstraZeneca-Bristol Myers deal, senior source says" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Fierce Pharma, Endpoints News and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 102d ago.
Quick answers
Why is "'No discussions' over AstraZeneca-Bristol Myers deal, senior source says" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- AstraZeneca may buck a decade of pharma strategy to buy U.S. scale cnbc.com · 102d ago
- Deal or No Deal, AstraZeneca Stock Is a Bargain WSJ · 102d ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger BioSpace · 102d ago
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks Yahoo Finance · 102d ago
- Soriot should explain the curious case of AstraZeneca’s non-deal The Guardian · 102d ago
- ‘No discussions’ ongoing for AstraZeneca-Bristol Myers merger: Reuters Fierce Pharma · 102d ago
- Merger talks between AstraZeneca, Bristol Myers are off Endpoints News · 102d ago
- 'No discussions' over AstraZeneca-Bristol Myers deal, senior source says Reuters · 102d ago
Topics
Related trends
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia
Bristol Myers Squibb is partnering with Nvidia to construct what it claims will be the most powerful AI supercomputer in the pharmaceutical industry.
Bob Myers goes on Rich Paul’s show, talks LeBron (duh), Jaylen Brown
NBA discourse intensifies as analysts and league insiders weigh in on potential free-agency moves for LeBron James, specifically regarding the Philadelphia 76ers.
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.